Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

Contact Us

Search

Intermittent fasting

Public_Health

Public Health Today—February 20, 2026

This weekly Public Health update covers major research and population-health…

Public_Health

Public Health Today—February 13, 2026

This weekly public health update covers recent developments in clinical…

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital Trends
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Healthcare and Pharma Trends
Rare Disease News
Health Mobile Apps Reports
Neuroscience News
Women's Health News
Public Health News
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

ACC 2026 Preview: Key Cardiology Highlights to Watch
Endocrinology Today—March 31, 2026
Obesity Today—March 31, 2026
Lucid Diligence Brief: Royalty Pharma and J&J partner in a $500M R&D deal for JNJ-4804
Hematology Today—March 30, 2026

Tags

Amazon Pharmacy ANRE Antibody-based therapeutics BRAF paradox breaker chronic disease CityUHK CMT SORD Cosentyx DALYs donanemab Eliquis Endocrinology News evinacumab Fondazione Telethon FOR46 GeneDx George Institute for Global Health imlunestrant Isturisa KMT2A lenacapavir life sciences software liver fibrosis LVV lyr-100 Lyra Therapeutics MFDS Korea model ops molecular glues Naval Medical Research Command Neurofibromatosis Type 1 Non covalent BTK inhibitor Paltusotine Pediatric psoriasis pig liver transplant Primary hyperparathyroidism PRISM AI radiology RNA splitting ruxolitinib RWD Sirius Therapeutics STENOVA Tetralogy of Fallot vorasidenib Zenas BioPharma

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

ACC 2026 Preview: Key Cardiology Highlights to Watch
Endocrinology Today—March 31, 2026
Obesity Today—March 31, 2026
Lucid Diligence Brief: Royalty Pharma and J&J partner in a $500M R&D deal for JNJ-4804
Hematology Today—March 30, 2026

TAGS

Amazon Pharmacy ANRE Antibody-based therapeutics BRAF paradox breaker chronic disease CityUHK CMT SORD Cosentyx DALYs donanemab Eliquis Endocrinology News evinacumab Fondazione Telethon FOR46 GeneDx George Institute for Global Health imlunestrant Isturisa KMT2A lenacapavir life sciences software liver fibrosis LVV lyr-100 Lyra Therapeutics MFDS Korea model ops molecular glues Naval Medical Research Command Neurofibromatosis Type 1 Non covalent BTK inhibitor Paltusotine Pediatric psoriasis pig liver transplant Primary hyperparathyroidism PRISM AI radiology RNA splitting ruxolitinib RWD Sirius Therapeutics STENOVA Tetralogy of Fallot vorasidenib Zenas BioPharma

Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

© 2026 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy